Biotech Values

[gfp927z]

Naplis, By 'pre-PDUFA ramp up' I meant the period leading up to the FDA approval decision (PDUFA date of Mar 18). Bios often move higher in this pre-PDUFA period, especially if the odds of approval look good, and the stock price is still relatively low.

Following approval, the company (APPA) will probably get sold by the majority owners (Tang and Baker Bros), so that enhances the upside for this play. Seeing approval as likely (505 b-2), and a post-approval buyout as likely, many investors may decide to stay long for the buyout.